An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Completed · Phase 1 · Has a placebo group

Conditions studied: Multiple Sclerosis, Acute Relapsing

In brief

This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.

Key facts

Study ID

NCT02398461

Run by

Acorda Therapeutics

People needed

27

Starts

2015-04-01

Expected to finish

2017-09-21

Last updated by the study team

2018-08-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females (18-70 years of age; < 104 kg)
• Capable of giving informed consent
• Meet diagnostic criteria for MS, as defined by revised (2010) McDonald criteria
• Present with a clinical acute relapse defined as a new or worsening neurological symptoms attributable to MS preceded by a stable or improving neurological state of at least 30 days, not associated with fever or infection, lasting at least 24 hours and accompanied by an objective physical (neurological) exam finding as confirmed by the Investigator
• Has at least one new, identifiable, measurable and active lesion on MRI (Gd+) meeting the criteria of the imaging charter.

You may not qualify if…

• Certain specified co-morbidities (including pregnancy)
• Taking certain proscribed medications
• A medical regimen that has changed in the month prior to screening
• Inability to undergo requisite MRI evaluations
• Drug or alcohol abuse
• Any other reason for which, in the opinion of the Investigator, the subject should not participate in the study.

Where it is running

• Acorda Site #12 — Long Beach, California, United States
• Acorda Site #3 — Sacramento, California, United States
• Acorda Site #7 — San Francisco, California, United States
• Acorda Site #11 — Aurora, Colorado, United States
• Acorda Site #16 — Centennial, Colorado, United States
• Acorda Site #22 — Chicago, Illinois, United States
• Acorda Site #14 — St Louis, Missouri, United States
• Acorda Site #19 — Teaneck, New Jersey, United States
• Acorda Site #10 — Rochester, New York, United States
• Acorda Site #18 — Dallas, Texas, United States
• Acorda Site #2 — Seattle, Washington, United States
• Acorda Site #6 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.